Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

NCT04103060 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Vitiligo

Interventions

DRUG: Cerdulatinib 0.37% gel
DRUG: Vehicle gel

Sponsor

Dermavant Sciences GmbH